WARNINGS O
General O
Rare O
instances O
of O
anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
occurred O
in O
patients O
receiving O
corticosteroid O
therapy O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Increased O
dosage O
of O
rapidly O
acting O
corticosteroids O
is O
indicated O
in O
patients O
on O
corticosteroid O
therapy O
subjected O
to O
any O
unusual O
stress B-Not_AE_Candidate
before O
, O
during O
, O
and O
after O
the O
stressful B-Not_AE_Candidate
situation O
. O

Cardio-Renal O
Average O
and O
large O
doses O
of O
corticosteroids O
can O
cause O
elevation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
sodium B-OSE_Labeled_AE
and O
water O
retention I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
excretion I-OSE_Labeled_AE
of I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
. O

These O
effects O
are O
less O
likely O
to O
occur O
with O
the O
synthetic O
derivatives O
except O
when O
used O
in O
large O
doses O
. O

Dietary O
salt O
restriction O
and O
potassium O
supplementation O
may O
be O
necessary O
. O

All O
corticosteroids O
increase B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
excretion I-OSE_Labeled_AE
. O

Literature O
reports O
suggest O
an O
apparent O
association O
between O
use O
of O
corticosteroids O
and O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
free I-OSE_Labeled_AE
wall I-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
after O
a O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
; O
therefore O
, O
therapy O
with O
corticosteroids O
should O
be O
used O
with O
great O
caution O
in O
these O
patients O
. O

Endocrine O
Corticosteroids O
can O
produce O
reversible O
hypothalamic B-OSE_Labeled_AE
- I-OSE_Labeled_AE
pituitary I-OSE_Labeled_AE
adrenal I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HPA I-OSE_Labeled_AE
) I-OSE_Labeled_AE
axis I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
with O
the O
potential O
for O
corticosteroid B-NonOSE_AE
insufficiency I-NonOSE_AE
after O
withdrawal O
of O
treatment O
. O

Adrenocortical B-NonOSE_AE
insufficiency I-NonOSE_AE
may O
result O
from O
too O
rapid O
withdrawal O
of O
corticosteroids O
and O
may O
be O
minimized O
by O
gradual O
reduction O
of O
dosage O
. O

This O
type O
of O
relative O
insufficiency O
may O
persist O
for O
months O
after O
discontinuation O
of O
therapy O
; O
therefore O
, O
in O
any O
situation O
of O
stress B-Not_AE_Candidate
occurring O
during O
that O
period O
, O
hormone O
therapy O
should O
be O
reinstituted O
. O

If O
the O
patient O
is O
receiving O
steroids O
already O
, O
dosage O
may O
have O
to O
be O
increased O
. O

Metabolic O
clearance O
of O
corticosteroids O
is O
decreased O
in O
hypothyroid B-Not_AE_Candidate
patients O
and O
increased O
in O
hyperthyroid B-Not_AE_Candidate
patients O
. O

Changes B-NonOSE_AE
in I-NonOSE_AE
thyroid I-NonOSE_AE
status I-NonOSE_AE
of O
the O
patient O
may O
necessitate O
adjustment O
in O
dosage O
. O

Infections O
General O
Patients O
who O
are O
on O
corticosteroids O
are O
more O
susceptible B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
than O
are O
healthy O
individuals O
. O

There O
may O
be O
decreased O
resistance O
and O
inability O
to O
localize O
infection B-NonOSE_AE
when O
corticosteroids O
are O
used O
. O

Infection B-OSE_Labeled_AE
with O
any O
pathogen O
( O
viral O
, O
bacterial O
, O
fungal O
, O
protozoan O
or O
helminthic O
) O
in O
any O
location O
of O
the O
body O
may O
be O
associated O
with O
the O
use O
of O
corticosteroids O
alone O
or O
in O
combination O
with O
other O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

These O
infections B-NonOSE_AE
may O
be O
mild O
to O
severe O
. O

With O
increasing O
doses O
of O
corticosteroids O
, O
the O
rate O
of O
occurrence O
of O
infectious B-NonOSE_AE
complications I-NonOSE_AE
increases I-NonOSE_AE
. O

Corticosteroids O
may O
also O
mask B-OSE_Labeled_AE
some O
signs O
of O
current O
infection I-OSE_Labeled_AE
. O

Fungal B-NonOSE_AE
Infections I-NonOSE_AE
: O
Corticosteroids O
may O
exacerbate B-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
and O
therefore O
should O
not O
be O
used O
in O
the O
presence O
of O
such O
infections B-NonOSE_AE
unless O
they O
are O
needed O
to O
control O
life B-NonOSE_AE
- I-NonOSE_AE
threatening I-NonOSE_AE
drug I-NonOSE_AE
reactions I-NonOSE_AE
. O

There O
have O
been O
cases O
reported O
in O
which O
concomitant O
use O
of O
amphotericin O
B O
and O
hydrocortisone O
was O
followed O
by O
cardiac B-NonOSE_AE
enlargement I-NonOSE_AE
and O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
( O
see O
PRECAUTIONS O
: O
Drug O
Interactions O
: O
Amphotericin O
B O
injection O
and O
potassium-depleting O
agents O
) O
. O

Special O
Pathogens O
: O
Latent O
disease O
may O
be O
activated O
or O
there O
may O
be O
an O
exacerbation O
of O
intercurrent O
infections B-OSE_Labeled_AE
due O
to O
pathogens O
, O
including O
those O
caused O
by O
Amoeba I-OSE_Labeled_AE
, O
Candida O
, O
Cryptococcus O
, O
Mycobacterium O
, O
Nocardia O
, O
Pneumocystis O
, O
Toxoplasma O
. O

It O
is O
recommended O
that O
latent B-Not_AE_Candidate
amebiasis I-Not_AE_Candidate
or O
active B-Not_AE_Candidate
amebiasis I-Not_AE_Candidate
be O
ruled O
out O
before O
initiating O
corticosteroid O
therapy O
in O
any O
patient O
who O
has O
spent O
time O
in O
the O
tropics O
or O
any O
patient O
with O
unexplained O
diarrhea B-Not_AE_Candidate
. O

Similarly O
, O
corticosteroids O
should O
be O
used O
with O
great O
care O
in O
patients O
with O
known O
or O
suspected O
Strongyloides B-Not_AE_Candidate
( I-Not_AE_Candidate
threadworm I-Not_AE_Candidate
) I-Not_AE_Candidate
infestation I-Not_AE_Candidate
. O

In O
such O
patients O
, O
corticosteroid B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
immunosuppression I-OSE_Labeled_AE
may O
lead O
to O
Strongyloides B-OSE_Labeled_AE
hyperinfection I-OSE_Labeled_AE
and O
dissemination O
with O
widespread O
larval O
migration O
, O
often O
accompanied O
by O
severe O
enterocolitis B-NonOSE_AE
and O
potentially O
fatal B-NonOSE_AE
gram B-NonOSE_AE
- I-NonOSE_AE
negative I-NonOSE_AE
septicemia I-NonOSE_AE
. O

Corticosteroids O
should O
not O
be O
used O
in O
cerebral B-Not_AE_Candidate
malaria I-Not_AE_Candidate
. O

Tuberculosis B-NonOSE_AE
: O
The O
use O
of O
corticosteroids O
in O
active B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
should O
be O
restricted O
to O
those O
cases O
of O
fulminating B-Not_AE_Candidate
or O
disseminated O
tuberculosis I-Not_AE_Candidate
in O
which O
the O
corticosteroid O
is O
used O
for O
the O
management O
of O
the O
disease O
in O
conjunction O
with O
an O
appropriate O
antituberculous B-NonOSE_AE
regimen O
. O

If O
corticosteroids O
are O
indicated O
in O
patients O
with O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
or O
tuberculin B-Not_AE_Candidate
reactivity I-Not_AE_Candidate
, O
close O
observation O
is O
necessary O
as O
reactivation O
of O
the O
disease O
may O
occur O
. O

During O
prolonged O
corticosteroid O
therapy O
, O
these O
patients O
should O
receive O
chemoprophylaxis O
. O

Vaccination O
: O
Administration O
of O
live O
or O
live O
, O
attenuated O
vaccines O
is O
contraindicated O
in O
patients O
receiving O
immunosuppressive B-NonOSE_AE
doses O
of O
corticosteroids O
. O

Killed O
or O
inactivated O
vaccines O
may O
be O
administered O
. O

However O
, O
the O
response O
to O
such O
vaccines O
can O
not O
be O
predicted O
. O

Immunization O
procedures O
may O
be O
undertaken O
in O
patients O
who O
are O
receiving O
corticosteroids O
as O
replacement O
therapy O
, O
e.g. O
, O
for O
Addison B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Viral B-NonOSE_AE
Infections I-NonOSE_AE
: O
Chickenpox B-NonOSE_AE
and O
measles B-NonOSE_AE
can O
have O
a O
more O
serious O
or O
even O
fatal B-NonOSE_AE
course O
in O
pediatric O
and O
adult O
patients O
on O
corticosteroids O
. O

In O
pediatric O
and O
adult O
patients O
who O
have O
not O
had O
these O
diseases O
, O
particular O
care O
should O
be O
taken O
to O
avoid O
exposure O
. O

The O
contribution O
of O
the O
underlying O
disease O
and/or O
prior O
corticosteroid O
treatment O
to O
the O
risk O
is O
also O
not O
known O
. O

If O
exposed O
to O
chickenpox B-NonOSE_AE
, O
prophylaxis O
with O
varicella B-NonOSE_AE
zoster I-NonOSE_AE
immune I-NonOSE_AE
globulin I-NonOSE_AE
( I-NonOSE_AE
VZIG I-NonOSE_AE
) O
may O
be O
indicated O
. O

If O
exposed O
to O
measles B-NonOSE_AE
, O
prophylaxis O
with O
immune O
globulin O
( O
IG O
) O
may O
be O
indicated O
. O

( O
See O
the O
respective O
package O
inserts O
for O
VZIG O
and O
IG O
for O
complete O
prescribing O
information O
. O
) O

If O
chickenpox B-NonOSE_AE
develops O
, O
treatment O
with O
antiviral O
agents O
should O
be O
considered O
. O

Ophthalmic O
Use O
of O
corticosteroids O
may O
produce O
posterior B-OSE_Labeled_AE
subcapsular I-OSE_Labeled_AE
cataracts I-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
with O
possible O
damage B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
optic I-NonOSE_AE
nerves I-NonOSE_AE
, O
and O
may O
enhance O
the O
establishment O
of O
secondary O
ocular B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due O
to O
bacteria O
, O
fungi O
, O
or O
viruses O
. O

The O
use O
of O
oral O
corticosteroids O
is O
not O
recommended O
in O
the O
treatment O
of O
optic B-Not_AE_Candidate
neuritis I-Not_AE_Candidate
and O
may O
lead O
to O
an O
increase O
in O
the O
risk O
of O
new O
episodes O
. O

Corticosteroids O
should O
not O
be O
used O
in O
active O
ocular B-Not_AE_Candidate
herpes I-Not_AE_Candidate
simplex I-Not_AE_Candidate
. O

